Timothy Campbell MD PhD
Hematologic Oncology
Vice President, Early Clinical Development Hematology and Cell Therapy
Join to View Full Profile
505 Parnassus AveSan Francisco, CA 94143
Phone+1 415-476-1525
Fax+1 415-502-1976
Dr. Campbell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2013 - 2015- University of California (San Francisco)Residency, Internal Medicine, 2010 - 2012
Indiana University School of MedicineClass of 2010
Certifications & Licensure
CA State Medical License 2012 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1036 citationsAnti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, Jesus G. Berdeja, Yi Lin, David S. Siegel, Sundar Jagannath
The New England Journal of Medicine. 2019-05-01 - 321 citationsNormal and Leukemic Stem Cell Niches: Insights and Therapeutic OpportunitiesKoen Schepers, Timothy B. Campbell, Emmanuelle Passegué
Cell Stem Cell. 2015-03-05 - 29 citationsOverexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulationTimothy B. Campbell, Sunanda Basu, Giao Hangoc, Wen Tao, Hal E. Broxmeyer
Blood. 2009-10-15
Journal Articles
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, M.D., Jesus Berdeja, M.D., Yi Lin, M.D., Ph.D., David Siegel, M.D., Ph.D., Sundar Jagannath, M.D., Deepu Madduri, M.D., Michaela Liedtke, M.D., Jacalyn Ro..., New England Journal of Medicine, 5/2/2019
Abstracts/Posters
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell TherapyTimothy B. Campbell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple MyelomaTimothy B. Campbell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
